Kowa Co Ltd (Kowa) is a global company primarily engaged in various industries, including textiles, pharmaceuticals, hospitality, and environmental solutions. Its trading activities include import, export, intermediate trade, and domestic sales of textiles, machinery, construction materials, chemicals, and commodities.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Kowa’s research and development initiatives are centered around the Tokyo Drug Discovery Research Center, Fuji Research Center, and Kowa Advanced Science Institute. The company is involved in the research and development of advanced technologies, particularly in prescription drugs targeting lifestyle-related diseases, immunity, inflammation, and sensory organs, eye disorders, and hearing and balance disorders. It also conducts safety testing, research into systems for efficiently delivering drugs to target sites, the creation of new dosage forms, the development of OTC drugs, and the manufacture of investigational drugs. The company's research and development focus on lifestyle-related diseases, immunology and inflammation, cancer disease, inflammatory disorders, skin disorders, sensory organs, The company’s pipeline products include Ripasudil for the treatment of Fuchs endothelial corneal dystrophy is currently in Phase III clinical stage; Pemafibrate being developed for the treatment of primary biliary cholangitis is currently in Phase II clinical stage; and Pemafibrate/Tofogliflozin, being developed for the treatment of nonalcoholic fatty liver disease is in Phase II stage. The R&D units of the company include the Tokyo Drug Discovery Research Center, Fuji Research Center, and the Center for Interdisciplinary Cardiovascular Sciences (CICS). The Tokyo Drug Discovery Research Center and Fuji Research Center are involved in drug discovery and development activities, while CICS, a joint research facility with Brigham and Women's Hospital, focuses on expanding the technological base and promoting research in cardiovascular sciences. In FY2025, the company spent JPY0.52 million on its R&D activities.